As of 2025-03-24, the EV/EBITDA ratio of WAVE Life Sciences Ltd (WVE) is -11.45. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. WVE's latest enterprise value is 1,182.17 mil USD. WVE's TTM EBITDA according to its financial statements is -103.28 mil USD. Dividing these 2 quantities gives us the above WVE EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 1.8x - 3.9x | 2.8x |
| Forward P/E multiples | 1.9x - 4.2x | 3.0x |
| Fair Price | 0.70 - (0.66) | (0.02) |
| Upside | -92.7% - -106.8% | -100.2% |
| Date | EV/EBITDA |
| 2025-03-18 | -11.98 |
| 2025-03-17 | -12.17 |
| 2025-03-14 | -12.26 |
| 2025-03-13 | -12.34 |
| 2025-03-12 | -13.14 |
| 2025-03-11 | -12.53 |
| 2025-03-10 | -11.03 |
| 2025-03-07 | -11.05 |
| 2025-03-06 | -12.20 |
| 2025-03-05 | -12.78 |
| 2025-03-04 | -13.77 |
| 2025-03-03 | -12.01 |
| 2025-02-28 | -12.78 |
| 2025-02-27 | -12.77 |
| 2025-02-26 | -12.83 |
| 2025-02-25 | -12.47 |
| 2025-02-24 | -12.65 |
| 2025-02-21 | -13.62 |
| 2025-02-20 | -13.91 |
| 2025-02-19 | -13.44 |
| 2025-02-18 | -13.47 |
| 2025-02-14 | -13.14 |
| 2025-02-13 | -13.13 |
| 2025-02-12 | -13.29 |
| 2025-02-11 | -12.55 |
| 2025-02-10 | -12.92 |
| 2025-02-07 | -13.68 |
| 2025-02-06 | -14.67 |
| 2025-02-05 | -15.27 |
| 2025-02-04 | -14.52 |
| 2025-02-03 | -14.70 |
| 2025-01-31 | -14.27 |
| 2025-01-30 | -15.00 |
| 2025-01-29 | -14.78 |
| 2025-01-28 | -14.97 |
| 2025-01-27 | -15.21 |
| 2025-01-24 | -14.92 |
| 2025-01-23 | -14.82 |
| 2025-01-22 | -14.40 |
| 2025-01-21 | -13.57 |
| 2025-01-17 | -13.41 |
| 2025-01-16 | -13.88 |
| 2025-01-15 | -14.12 |
| 2025-01-14 | -13.62 |
| 2025-01-13 | -13.82 |
| 2025-01-10 | -14.23 |
| 2025-01-08 | -15.65 |
| 2025-01-07 | -16.51 |
| 2025-01-06 | -16.44 |
| 2025-01-03 | -17.15 |